Literature DB >> 630963

Disproportionate ventricular thickening in patients with systemic hypertension.

B J Maron, J E Edwards, S E Epstein.   

Abstract

To determine the prevalence and characteristics of disproportionate ventricular septal thickening (septal-free wall ratio of greater than or equal to 1.3) in a population of patients with severe chronic hypertension, which was unassociated with coronary arterial disease, 33 patients were studied at necropsy. The overall prevalence of disproportionate septal thickening was relatively low, ie, two (6 percent) of the 33 patients. The septal-free wall ratio in both of these patients was 1.3. Disproportionate septal thickening appeared to be secondary to the left ventricular pressure overload, rather than to coexistent genetically transmitted hypertrophic cardiomyopathy. This conclusion was based on the following facts: (1) numerous disorganized cardiac muscle cells, characteristic of hypertrophic cardiomyopathy, were not present in the ventricular septum of either patient with disproportionate septal thickening; and (2) echocardiographic studies performed in first-degree relatives of one of the two patients did not disclose disproportionate septal thickening. Hence, disproportionate septal thickening may occur as a secondary manifestation of left ventricular pressure overload that is present in patients with systemic hypertension, but this association appears to be relatively uncommon.

Entities:  

Mesh:

Year:  1978        PMID: 630963     DOI: 10.1378/chest.73.4.466

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Evolution of ventricular hypertrophy and myocardial mechanics in physiological and pathological hypertrophy.

Authors:  Fatih Yalçin; Nagehan Kucukler; Oscar Cingolani; Blaid Mbiyangandu; Lars Sorensen; Aurelio Pinherio; M Roselle Abraham; Theodore P Abraham
Journal:  J Appl Physiol (1985)       Date:  2018-01-04

2.  Prevalence, clinical correlates, and prognosis of discrete upper septal thickening on echocardiography: the Framingham Heart Study.

Authors:  Tulio Diaz; Michael J Pencina; Emelia J Benjamin; Jayashri Aragam; Deborah L Fuller; Karol M Pencina; Daniel Levy; Ramachandran S Vasan
Journal:  Echocardiography       Date:  2008-10-23       Impact factor: 1.724

Review 3.  Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment.

Authors:  Maria-Angela Losi; Stefano Nistri; Maurizio Galderisi; Sandro Betocchi; Franco Cecchi; Iacopo Olivotto; Eustachio Agricola; Piercarlo Ballo; Simona Buralli; Antonello D'Andrea; Arcangelo D'Errico; Donato Mele; Susanna Sciomer; Sergio Mondillo
Journal:  Cardiovasc Ultrasound       Date:  2010-03-17       Impact factor: 2.062

Review 4.  Basal septal hypertrophy.

Authors:  Mihir A Kelshiker; Jamil Mayet; Beth Unsworth; Darlington O Okonko
Journal:  Curr Cardiol Rev       Date:  2013-11

5.  Mouse models for the study of postnatal cardiac hypertrophy.

Authors:  A Del Olmo-Turrubiarte; A Calzada-Torres; G Díaz-Rosas; I Palma-Lara; R Sánchez-Urbina; N A Balderrábano-Saucedo; H González-Márquez; P Garcia-Alonso; A Contreras-Ramos
Journal:  Int J Cardiol Heart Vasc       Date:  2015-03-06

6.  Could early septal involvement in the remodeling process be related to the advance hypertensive heart disease?

Authors:  Fatih Yalçin; Caner Topaloglu; Nagehan Kuçukler; Mehmet Ofgeli; Theodore P Abraham
Journal:  Int J Cardiol Heart Vasc       Date:  2015-04-08

7.  Systolic anterior motion of mitral valve following resection of subaortic membrane and intracardiac repair of tetralogy of fallot.

Authors:  Krishna Prasad Gourav; Bhupesh Kumar; Imran Bhat; Anand K Mishra
Journal:  Ann Card Anaesth       Date:  2020 Jul-Sep

Review 8.  Basal Septal Hypertrophy as the Early Imaging Biomarker for Adaptive Phase of Remodeling Prior to Heart Failure.

Authors:  Fatih Yalçin; Hulya Yalçin; Nagehan Küçükler; Serbay Arslan; Oguz Akkuş; Alparslan Kurtul; Maria Roselle Abraham
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.